(1) Goals of project: - To study the activities of monoclonal antibodies (mAbs) raised against HIV-1 envelope (gp120), CD4, gp120/CD4 complexes, or the HIV-1 co-receptors, on HIV-1 fusion/infection of primary human cells. - To examine the effects of such mAbs on the normal biological functions of primary human cells. (2) Experimental approach: - We have collected a panel of murine mAbs specific for the HIV-1 gp 120 or for the CD4 molecules, that bind with increased avidity to the gp120/CD4 complex and may be involved in co-receptor recruitment. - These mAbs were tested for their effects on HIV-1 fusion/infection (both M-tropic and T-tropic strains), and for their activity in various assays designed to measure the formation of tri-molecular complexes between gp120,CD4, and the HIV-1 co-receptors. (3) Major Findings: - MAb CG10 was generated against soluble gp120(LAI)/CD4 complexes. It is gp120-specific but strictly complex-dependent. It was recently shown to interact with the region in gp120 that """"""""faces"""""""" and possibly interact with the co-receptor molecules on target cells. In fusion/infectivity assays, we found that the CG10 mAb does not block but rather enhances viral fusion. Both T-tropic and M-tropic env-mediated fusion was enhanced, albeit at different optimal doses. These findings suggest that mAbs such as CG10 may have deleterious rather than protective effects in vivo by increasing cell-to-cell viral transfer. (Shirley Lee et al. J. Virol. 71:6671-6676, 1997) - CD4-specific mAbs (CG1,7,8) that bind with 10 fold higher avidity to preformed CD4/gp120 complexes than to CD4, were tested in multiple assays of HIV-1 co-receptor (CXCR4 or CCR5) recruitment. In three different assays these mAbs were found to stabilize the association of co-receptor, gp120, and CD4 in tri-molecular complexes. Such antibodies may be used as tools to dissect the steps leading to HIV-1 cell entry. In vivo, they may lead to an increase in viral-cell entry resulting in increased viral loads. In press, AIDS Research and Human Retroviruses.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Intramural Research (Z01)
Project #
1Z01BK003002-05
Application #
6101175
Study Section
Special Emphasis Panel (LRR)
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost